Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00982033 · ClinicalTrials.gov registry record · Phase 4
Effects of Aliskiren on Patient With Heart Failure and a Normal Ejection Fraction
A Phase 4 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
NCT00982033 is a Phase 4 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 52 participants.
The verdict
NCT00982033, a Phase 4 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine whether treatment with aliskiren (300 mg) compared to placebo will improve treadmill exercise time in older (age ≥ 55 years) patients with heart failure and normal ejection fraction (HFNEF).
Interventions
- DRUG placebo
- DRUG aliskiren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2009-07 |
| Est. Completion | 2011-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00982033
The ClinicalTrials.gov registry entry for NCT00982033 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00982033 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00982033 about?
NCT00982033 is a clinical study titled "Effects of Aliskiren on Patient With Heart Failure and a Normal Ejection Fraction". The primary objective of this study is to determine whether treatment with aliskiren (300 mg) compared to placebo will improve treadmill exercise time in older (age ≥ 55 years) patients with heart failure and normal ejection fraction (HFNEF).
What is the current status of trial NCT00982033?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2009-07. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00982033?
The interventions under investigation include: placebo (DRUG), aliskiren (DRUG).
Who is sponsoring clinical trial NCT00982033?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.